Skip to content
★ Sign in to follow
MI

Myung In Pharmaceutical Ltd. Stock: price and insider trades · South Korea

명인제약

KR·Mcap ₩615.4BHealth Care

No insider purchase over the last 90 days. The latest, by 이자영, was filed 08 May 2026.

Myung In Pharmaceutical Ltd.: what insiders have been doing

Myung In Pharmaceutical Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). From 2 November 2025 to 2 November 2026, the disclosure feed for Myung In Pharmaceutical Ltd. logged 5 filings by 4 insiders.

Open-market activity splits into 2 purchases and 2 sales; 2 insiders sit on the buying side and 1 insider on the selling side. The totals exclude 4 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.

The latest purchase dates back some time: it was published 186 days ago, on 8 May 2026. Most trades are made public on the day they happen. The shorter that gap, the sooner other investors can see what insiders have done.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 5 filings, this issuer sits below that mark. Looking back to 2026, when coverage begins, insiders filed 2 purchases and 2 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.

Insider Decl.
5
Thresholds
n/a
Buy Volume
€103M
2 ops. · all time
Sell Volume
€35M
2 ops. · all time

Who traded when

BuySale
이행명2 sales
이선영1 buy
이자영1 buy

Since the insiders bought

  • Filed 08 May 2026 · 186 days ago · €47.2M
    -24.2%
    Entry ₩52,900 · Close 30 Oct 2026 ₩40,100
  • Filed 08 May 2026 · 186 days ago · €55.4M
    -24.2%
    Entry ₩52,900 · Close 30 Oct 2026 ₩40,100

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 475 of 26,911 companies
84.9
score / 100
Value
84
Quality
86
FCF yld7.6%
Earn yld13%
EV/EBITDA5.4x
ROE13%
Gross mgn61%
Net mgn28%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩42,150
Analyst consensus
·
Income statement
Revenue₩287.3B
Gross profit₩174B61% margin
EBITDA₩113.3B39% margin
Net income₩81.4B30.3% margin
Balance sheet & cash
Market cap₩615.4B
Total debt₩1.4B
Free Cash Flow₩46.7B
Debt / Equity0%
Profitability & ownership
ROE12.9%
ROA8.3%
% insiders76.3%
% institutions0.3%
Last declaration on 8 May 2026
Declarations5 total
  • ▼
    Executives
    €1.6Mest.0DART
    50,000 sharesKRXDART:20260508000794
  • ▲
    -Executives
    €47.2Mest.0DART
    1,500,000 sharesShareKRXDART:20260508000954
    Canonical exit: 6 Aug 2026 (T+90)
  • ▲
    -Executives
    €55.4Mest.0DART
    1,760,000 sharesShareKRXDART:20260508000926
    Canonical exit: 6 Aug 2026 (T+90)
  • ▼
    회장Executives
    €33.4Mest.0DART
    1,060,000 sharesShareKRXDART:20260508000869
  • ●
    사장Executives(filed)
    0DART
    ShareKRXDART:20260406003844

5 of 5 declarations

About Myung In Pharmaceutical Ltd.

명인제약 is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development and manufacturing of pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations